NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Annovis Bio, Inc. ANVS
7 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
$-28.9M
Growth
—
Revenue, FY2025 · full 7-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -28.9
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -220.6%
Each USD of equity lost 221 cents this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.40 | −2.31 | −6.23 | −3.10 | −1.90 | −0.87 | −3.51 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | −220.6 | −3159.1 | −546.4 | −69.6 | −55.7 | · | · |
| Shares out B | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 7 of 19 fiscal years. 48 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019